Upsher-Smith Enters Into Exclusive Agreement with Emphascience for Development of Specialty Branded Generic Product

On July 29, 2022 Upsher-Smith Laboratories, LLC (Upsher-Smith) reported that it has entered into an exclusive agreement with Emphascience, Inc. (Emphascience) to support the development of a specialty branded generic product (Press release, Upsher-Smith Laboratories, JUL 29, 2022, View Source [SID1234617231]). This collaboration is part of Upsher-Smith’s company-wide effort to grow the Company’s portfolio of products through strategic partnerships and product acquisitions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Emphascience will develop the product exclusively for Upsher-Smith. Upsher-Smith will manufacture, market and distribute it under its own label in the U.S. upon FDA approval. Financial terms related to the deal have not been disclosed.

"Upsher-Smith is committed to growing its ANDA portfolio through external programs and strategic partnerships that will drive volume to our new manufacturing facility," said Rich Fisher, President and COO, Upsher-Smith. "We look forward to working with Emphascience, a company that is well known for its development expertise as we continue to expand our portfolio with high-touch generic products that could fill unmet patient needs."

Rebanta Bandyopadhyay, Ph.D., President and CEO of Emphascience added, "We are excited to partner with such a well-regarded, trusted, quality-conscious, and patient-focused pharmaceutical company as Upsher-Smith Laboratories, to apply our technical skills and scientific acumen in designing and developing high quality, innovative medicines that truly impact patients’ lives."

Upsher-Smith will open its world-class manufacturing facility in Maple Grove, MN later this year. The new, 270,000 square foot facility will have fully up-to-date serialization and packaging capabilities and has capacity and capabilities that can support contract manufacturing for third parties. To learn more, visit www.upsher-smith.com.